RecruitingNCT07193329
Psychological Distress in Malignant Tumor Patients: Effects on Treatment Adherence, Outcomes, and Quality of Life
Sponsor
Gang Chen, MD
Enrollment
2,000 participants
Start Date
Jul 22, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
The goal of this observational study is to learn about the Psychological Distress in Malignant Tumor Patients about Effects on Treatment Adherence, Outcomes, and Quality of Life. The main question it aims to answer is: Does Psychological Distress affect Malignant Tumor Patients' Effects on Treatment Adherence, Outcomes, and Quality of Life? Malignant Tumor Patients with or without Psychological Distress will answer GAD-7 and PHQ-9 and their Treatment Adherence, Outcomes, and Quality of Life be recorded for 3 years.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- (1) Confirmed malignant tumors by imaging or pathology (such as hepatobiliary carcinoma, gastric cancer, breast cancer, lung cancer, etc.)
- (2) Planning to receive or currently undergoing systemic treatment (such as surgery, chemotherapy, TACE, targeted therapy, etc.)
- (3) Age ≥18 years old
- (4) Sign the informed consent form and voluntarily participate in this study
Exclusion Criteria3
- (1) Combined with severe systemic diseases (such as severe cardiovascular and cerebrovascular diseases)
- (2) There is severe cognitive impairment and it is impossible to complete the questionnaire assessment
- (3) Incomplete clinical data or loss to follow-up
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07193329
Related Trials
Self-Help Plus for Distress in University Students
NCT066062493 locations
EMDR Integrative Group Protocol and Individual Treatment for Patients With Cancer: A Pilot Study
NCT074470891 location
Hypnotic Communication in Cardiology: A Randomized Controlled Trial
NCT074242091 location
Clinical Application of Al18F-NOTA-FAPI-04 PET/CT or PET/MRI Imaging in Malignant Tumor,Cardiovascular or Immune Disease
NCT074002241 location
A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
NCT046866821 location